Stockscreener 앱 받기
5.12
2.29%
-0.12
전일 마감가:
$5.24
열려 있는:
$5.19
하루 거래량:
1.12M
Relative Volume:
0.71
시가총액:
$1.05B
수익:
-
순이익/손실:
$-118.84M
주가수익비율:
-9.5808
EPS:
-0.5344
순현금흐름:
$-101.06M
1주 성능:
+0.00%
1개월 성능:
-8.24%
6개월 성능:
+23.37%
1년 성능:
+57.06%
1일 변동 폭
$5.065
$5.27
1주일 범위
$4.835
$5.35
52주 변동 폭
$1.89
$7.005
사바라 Stock (SVRA) Company Profile
명칭
Savara Inc
전화
51285113796
주소
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
5.12 | 1.05B | 0 | -118.84M | -101.06M | -0.5344 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
사바라 Stock (SVRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-24 | 재개 | Oppenheimer | Outperform |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-08-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-05-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-12-20 | 개시 | Wells Fargo | Overweight |
| 2024-11-13 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-15 | 개시 | JMP Securities | Mkt Outperform |
| 2023-11-07 | 개시 | Guggenheim | Buy |
| 2023-05-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-31 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-03-16 | 개시 | Piper Sandler | Overweight |
| 2021-03-15 | 개시 | Oppenheimer | Outperform |
| 2019-06-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-13 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | 재개 | ROTH Capital | Neutral |
| 2018-01-03 | 개시 | Ladenburg Thalmann | Buy |
| 2017-09-27 | 재개 | ROTH Capital | Buy |
| 2017-09-22 | 개시 | Jefferies | Buy |
| 2017-09-11 | 개시 | JMP Securities | Mkt Outperform |
모두보기
사바라 주식(SVRA)의 최신 뉴스
SVRA stock slips post-market after FDA delays decision on pulmonary therapy - MSN
Savara Grants Equity Awards to 24 New Employees - MyChesCo
US High Growth Tech Stocks To Watch - Sahm
Savara Inc. ticks higher amid takeover speculation - MSN
FDA Extends Review of Savara’s Molgramostim Application to November - MyChesCo
Savara to Present Molgramostim Data at ATS 2026 Conference - MyChesCo
Assessing Savara (SVRA) Valuation After FDA Extends Priority Review For Molgramostim - Yahoo Finance
Savara’s FDA Review Extension Keeps Molgramostim Thesis Intact But Delayed - Sahm
Savara Inc ($SVRA) CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] Savara Inc SEC Filing - Stock Titan
Savara (NASDAQ: SVRA) seeks big share boost and equity plan expansion - Stock Titan
Savara (NASDAQ:SVRA) Coverage Initiated by Analysts at Oppenheimer - MarketBeat
Savara (SVRA) Stock: Pricing Efficiency Review | Q4 2025: EPS Misses EstimatesLow Growth - Cổng thông tin điện tử tỉnh Lào Cai
SVRA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Savara Inc. (NASDAQ:SVRA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Savara (SVRA) Stock: Why It Could Double (Mini Selloff) 2026-04-20Profit Potential - Cổng thông tin điện tử tỉnh Lào Cai
Savara reports 2025 results, advances MOLBREEVI toward approval - MSN
Savara Announces New Employment Inducement GrantApril 17, 2026 - BioSpace
FY2026 EPS Estimates for Savara Decreased by Lifesci Capital - MarketBeat
Savara Inc stock (US80633A1025): Why does its rare disease focus matter more now for investors? - AD HOC NEWS
Savara Says UK Regulator Accepts MOLBREEVI Application - MyChesCo
Savara (NASDAQ:SVRA) Strengthens Market Presence In Nasdaq Today Biotech Segment - Kalkine Media
H.C. Wainwright Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛
Savara (NASDAQ:SVRA) Stock Price Up 2.5%Here's Why - MarketBeat
How Investors Are Reacting To Savara (SVRA) FDA Priority Review Extension For Molgramostim In Autoimmune PAP - simplywall.st
FDA extends review of Savara’s molgramostim application By Investing.com - Investing.com India
Savara, Inc. (SVRA) Stock Analysis: A Biotech Gem With 91.71% Potential Upside - DirectorsTalk Interviews
Savara (SVRA) Receives FDA Review Extension for Molgramostim App - GuruFocus
Piper Sandler Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $16 - 富途牛牛
LifeSci Capital Maintains Savara(SVRA.US) With Buy Rating, Cuts Target Price to $9 - Moomoo
Savara gets FDA review extension for lead asset - MSN
Savara gets FDA review extension for lead asset (SVRA:NASDAQ) - Seeking Alpha
Savara (SVRA) Receives Three-Month Extension for BLA Review - GuruFocus
FDA Extends Review Period for Savara's Molgramostim BLA in Autoimmune PAP - National Today
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - BioSpace
FDA extends review of Savara’s molgramostim application - Investing.com
SVRA Stock Slips Post-Market After FDA Delays Decision On Pulmonary Therapy - Stocktwits
Savara to present molgramostim data at ATS conference in May - Investing.com
사바라 (SVRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
사바라 주식 (SVRA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| McCracken Joseph S | Director |
Feb 16 '26 |
Option Exercise |
1.76 |
1,807 |
3,180 |
302,644 |
| RAMSAY DAVID A | Director |
Dec 19 '25 |
Sale |
6.06 |
20,000 |
121,220 |
2,533,642 |
2.45%
자본화:
|
볼륨(24시간):